Gilead revenue rises 10% to $7.8 billion in second quarter of 2026
Key Facts
Gilead Sciences reported a 10% increase in second-quarter 2026 revenue to $7.8 billion from the same period in 2025, driven by growth in product sales. HIV product sales totaled $5.7 billion, up 12% year over year, according to the company’s results. These figures are the latest documented quarterly results available for the company. The annual sales range attributed by an earlier draft to a later update could not be verified in an official announcement or an open news report. This article therefore does not present that range as confirmed news or attribute a specific reason for raising the forecast to the company.
Chief Executive Daniel O’Day said HIV drug sales grew 12% in the second quarter, citing “continued strength in treatment and rapid expansion in the pre-exposure prophylaxis business.” The company said sales growth supported an increase in its 2026 core business revenue forecast. In guidance issued on August 4, Gilead set annual product sales at $30.1 billion to $30.4 billion, compared with the previous range of $30.0 billion to $30.4 billion in May. This shows that the August guidance made a limited adjustment to the lower end, while leaving the upper end unchanged. That earlier guidance alone does not establish any subsequent change to the range.
The segment’s growth came as Biktarvy sales rose 7% to $3.8 billion in the second quarter from the same period a year earlier. Gilead attributed the performance to higher realized pricing and demand, along with favorable inventory dynamics. Descovy sales rose 48% to $967 million, with the company attributing the increase mainly to realized pricing and demand. The results show differing growth rates between the two products, with revenue from each rising year over year. They also place the products’ sales within the broader increase in HIV products recorded for the quarter.
In another part of its August guidance, Gilead cut its 2026 Yeztugo sales forecast to about $300 million, compared with a forecast of about $600 million in its May guidance. The adjustment runs counter to the growth in HIV drug sales and affects the outlook for annual product sales. In September, the company announced an expansion of its royalty-free voluntary licensing agreements to include investigational lenacapavir for once-yearly HIV prevention in 120 high-prevalence countries, most of them low-income or lower-middle-income countries. The announcement relates to plans to make a potential preventive treatment available, while the drug remains investigational, according to the company’s wording.
Gilead said the target date for a U.S. Food and Drug Administration decision on its application for a potential once-weekly oral formulation of Yeztugo for pre-exposure prophylaxis is February 2, 2027. In trading, the company’s shares, listed under ticker GILD, closed at $159.2 on October 28, 2026. The data provided contain no details on the stock’s trading range during the session or evidence that the close came in response to a change in guidance. The upcoming regulatory decision date remains a specified milestone on the company’s calendar, alongside its quarterly results and guidance published in August.